Effect of Majoone jayyad in improving quality of life in person with residual hemiplagia

Effect of Majoone jayyad on motor function and quality of life in subjects with residual hemiplagia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024443

Enrollment

Registered

2020-04-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G819- Hemiplegia, unspecified

Interventions

Intervention1: Majoon jayyad: 7 gms orally of Majoon jayyad at morning and night for 2 months Control Intervention1: Placebo: 7 gms placebo orally daily at morning and night for 2 months

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient must have had an ischemic vascular lesion, as documented by CT scan or MRI. 2.Stroke occurs more than 2 months prior to study enrolment. 3.Neurological and medically stable patients as determine by medical history and documented neurological examination. 4.Score on the UE-FM of >=28 to 5.Score on the lower limb(FMA-LE 6.Age>=21 years at time of enrolment. 7. Both males and females.

Exclusion criteria

Exclusion criteria: 1. Hemorrhagic stroke 2. > 1 stroke 3. Any neurologic condition or physical condition that impairs function of the affected extremities. 4. History of seizure disorder or spontaneous siezure that has occured one month or longer after the stroke. 5. Serious neurological conditions including CNS vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis, or arteriovenous malformations. 6. Severe sensory deficit. 7. Inability to understand, cooperate and adhere to the study procedure. 8. History of spinal cord injury, brain injury or spontaneous subdural or epidural hematoma that has resulted in neurologic deficit. 9. Pregnancy and lactation. 10. History of potentially fatal cardiac arrythmias.

Design outcomes

Primary

Measure	Time frame
Improvement in motor function Improvement in quality of life in patient with residual hemiplagia Disability limitationTimepoint: 0th day and 60th day of treatment	—

Secondary

Measure	Time frame
Improvement in grip strength Improvement in Range of motion Improvement in motor power or spasticity Improvement of gait and speed Improvement of Quality of lifeTimepoint: 0th day, 15th day, 30th day, 45th day, 60th day	—

Countries

India

Contacts

Public ContactDr Zarnigar

National Institute of Unani Medicine

zarnigarriaz@rediffmail.com7022669959

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026